Author: Jessica.F

The reaction of an aromatic heterocycle with a proton is called a protonation. One of articles about this theory is 《Some derivatives of 6-bromo-8-methylquinoline and 6-chloro-8-methylquinoline》. Authors are Irving, Thurman A.; Greene, Joseph L. Jr.; Peterson, Joe G.; Capps, Julius D..The article about the compound:6-Bromo-8-methylquinolinecas:178396-31-1,SMILESS:CC1=CC(Br)=CC2=C1N=CC=C2).Recommanded Product: 178396-31-1. Through the article, more information about this compound (cas:178396-31-1) is conveyed.

cf. C.A. 44, 9965f. 6-Chloro-8-methylquinoline picrate m. 223-4°. 2-Acetamido-5-bromo-4-nitrotoluene (I), m. 153-4°; the Cl analog m. 142-3° [Reverdin and Crepieux, Ber. 33, 2505(1900), gave 262°]. Skraup ring closure of 8 g. I gives 1.9 g. 6-bromo-8-methyl-5-nitroquinoline (II), m. 117-18°; 6-Cl analog (III), m. 99-100°, 9.3%. By the previous method, II yields 76% crude 6-bromo-1,8-dimethyl-2(1H)-quinolone (IV), m. 76-81°, which with POCl3-PCl5 gives 76% 6-bromo-2-chloro-8-methylquinoline (V), m. 120-1°; 6-Cl analog of IV, m. 64-5°, 75%; 6-Cl analog (VI) of V, m. 121-2°, 78%. V (2 g.) in 25% (by volume) H2SO4, heated 2 h. at 175-80° (autoclave), gives 84% 6-bromo-2-hydroxy-8-methylquinoline, m. 280-1°; 6-Cl analog (9.1 g. from 10 g. VI), m. 265-6°. I (25 g.) and 20 mL. Me2SO4, heated 1 h. at 150-70° and 1.5 h. at 145° and oxidized with 30% H2O2 at 55-65°, give 65% 6-bromo-1,8-dimethyl-5-nitroquinolone (VII), m. 158-9°; crude Cl analog, m. 121-2° (decomposition). VII yields 69% 2,6-dibromo-8-methyl-5-nitro-2(1H)-quinoline, m. 160-1°; 2,6-di-Cl compound, m. 137-8°, 73%. 6-Bromo-2-hydroxy-8-methyl-5-nitroquinoline, m. 311-12°, 87%; 6-Cl analog, m. 271-2°. Reduction in Me2CO or absolute EtOH over Raney Ni gives the following: 5-amino-6-bromo-8-methylquinoline, m. 116-17°, 73% (Ac derivative, m. 235-6°, 81%; Bz derivative, m. 210-11°, 69%); 6-Cl analog, m. 113-14°, 92% (Ac derivative, m. 225-6°, 82%; Bz derivative, m. 193-4°, 79%); 5-amino-2-chloro-6-bromo-8-methylquinoline, m. 127-8° (6 g. from 10 g. NO2 compound) (Ac derivative, m. 272-3°, 84%; Bz derivative, m. 252-3°, 60%); 5-amino-2,6-dichloro-8-methylquinoline, m. 132-3°, 96% (Ac derivative, m. 265-6°, 84%; Bz derivative, m. 253-4°, 65%); 5-amino-2-hydroxy-6-bromo-8-methylquinoline, m. 238-9°, 89% [Ac derivative, m. 318-19° (decomposition); Bz derivative, m. 297-8°, 75%]; 5-amino-2-hydroxy-6-chloro-8-methylquinoline (Ac derivative, m. above 340°, 54%; Bz derivative, m. 331-2°, 93%). By the Bart reaction (cf. Capps and Hamilton, C.A. 32, 8421.4) were prepared: 6-bromo-8-methyl-5-quinoline arsonic acid, m. 244-5° (decomposition), 10.5%; 6-Cl analog, m. 255-6°, 17%; 2-chloro-6-bromo analog, m. above 330°, 7.7%; 2,6-di-Cl compound, m. 302-3°, 6.7%; 2-hydroxy-6-bromo analog, m. above 330°, 8.8%; 2-hydroxy-6-chloro analog, m. 325-6°, 6.5%.

From this literature《Some derivatives of 6-bromo-8-methylquinoline and 6-chloro-8-methylquinoline》,we know some information about this compound(178396-31-1)Recommanded Product: 178396-31-1, but this is not all information, there are many literatures related to this compound(178396-31-1).

Reference:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

Recommanded Product: 41575-94-4. Aromatic heterocyclic compounds can also be classified according to the number of heteroatoms contained in the heterocycle: single heteroatom, two heteroatoms, three heteroatoms and four heteroatoms. Compound: cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II), is researched, Molecular C6H12N2O4Pt, CAS is 41575-94-4, about Evaluating patient-reported symptoms and late adverse effects following completion of first-line chemotherapy for ovarian cancer using the MOST (Measure of Ovarian Symptoms and Treatment concerns).. Author is Beesley, Vanessa L; Ross, Tanya L; King, Madeleine T; Campbell, Rachel; Nagle, Christina M; Obermair, Andreas; Grant, Peter; DeFazio, Anna; Webb, Penelope M; Friedlander, Michael L; OPAL Study Group.

OBJECTIVES: Knowledge on the course of symptoms patients with ovarian cancer experience is limited. We documented the prevalence and trajectories of symptoms after first-line chemotherapy using the Measure of Ovarian Symptoms and Treatment concerns (MOST). METHODS: A total of 726 patients who received platinum-based chemotherapy for ovarian cancer were asked to complete the MOST every 3 months, beginning 6 months post-diagnosis and continuing for up to 4 years. We used descriptive statistics to examine temporal changes in MOST-S26 index scores for disease or treatment-related (MOST-DorT), neurotoxicity (MOST-NTx), abdominal (MOST-Abdo), and psychological (MOST-Psych) symptoms, and wellbeing (MOST-Wellbeing) and selected individual symptoms. We used group-based trajectory models to identify groups with persistently poor symptoms. RESULTS: The median MOST-Abdo, MOST-DorT and MOST-Wellbeing score were worst at chemotherapy-end but improved and stabilised by 1, 3 and 12 months after treatment, respectively. The median MOST-NTx score peaked at 1 month after treatment before improving, while the median MOST-Psych score did not change substantially over time. Long-term moderate-to-severe fatigue (32%), trouble sleeping (31%), sore hands and feet (21%), pins and needles (20%) and anxiety (18%) were common. Trajectory models revealed groups of patients with persistent symptoms had MOST-DorT scores above 30 and MOST-NTx scores above 40 at treatment-end. CONCLUSIONS: Although many patients report improvements in symptoms by 3 months after first-line chemotherapy for ovarian cancer, patients who score > 30/100 on MOST-S26-DorT or > 40/100 on MOST-S26-NTx at the end of chemotherapy are likely to have persistent symptoms. The MOST could triage this at-risk subset for early intervention.

There is still a lot of research devoted to this compound(SMILES：O=C1C2(CCC2)C(O[Pt]O1)=O.N.N)Recommanded Product: 41575-94-4, and with the development of science, more effects of this compound(41575-94-4) can be discovered.

Reference:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

Nikitenko, S. I.; Moisy, Ph.; Seliverstov, A. F.; Blanc, P.; Madic, C. published an article about the compound: Bis(2,2,6,6-tetramethyl-3,5-heptanedionato)nickel(II)( cas:14481-08-4,SMILESS:CC(C)(C1=O[Ni+2]2(O=C(C(C)(C)C)[CH-]1)O=C([CH-]C(C(C)(C)C)=O2)C(C)(C)C)C ).Safety of Bis(2,2,6,6-tetramethyl-3,5-heptanedionato)nickel(II). Aromatic heterocyclic compounds can be classified according to the number of heteroatoms or the size of the ring. The authors also want to convey more information about this compound (cas:14481-08-4) through the article.

The kinetics of metal β-diketonates sonolysis was studied in hexadecane solutions using a UV/VIS spectrophotometric technique. The following complexes were prepared and studied: Cu(HFAA)2, Cu(DPM)2, Fe(ACAC)3, Ni(DPM)2, Er(DPM)3, Nd(DPM)3, Th(DPM)4, UO2(BTFA)2 · TOPO, and Np(HFAA)4, where HHFAA is hexafluoroacetylacetone, HDPM is dipivaloylmethane, HACAC is acetylacetone, HBTFA is benzoyltrifluoroacetone, and TOPO is trioctylphosphine oxide. Sonolysis was performed under the following conditions: ultrasonic frequency 22 kHz, intensity of ultrasound 3-5 W cm-2, temperature 70-92 °C, Ar atm. The kinetic behavior of the studied complexes are interpreted using a two-site model of the sonochem. processes. In the case of metal β-diketonates with high vapor pressure the sonochem. reactions tend to occur in the gaseous phase of the cavitating bubbles. The sonolysis of less volatile complexes first occur in the liquid reaction zone surrounding the bubbles. Sonication of the studied complexes results in the formation of X-ray amorphous products consisted of a mixture of metal β-diketonates partial degradation products. Heating of as-prepared sonication products in air yields nanocrystalline oxides of corresponding metals.

There is still a lot of research devoted to this compound(SMILES：CC(C)(C1=O[Ni+2]2(O=C(C(C)(C)C)[CH-]1)O=C([CH-]C(C(C)(C)C)=O2)C(C)(C)C)C)Safety of Bis(2,2,6,6-tetramethyl-3,5-heptanedionato)nickel(II), and with the development of science, more effects of this compound(14481-08-4) can be discovered.

Reference:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

Heterocyclic compounds can be divided into two categories: alicyclic heterocycles and aromatic heterocycles. Compounds whose heterocycles in the molecular skeleton cannot reflect aromaticity are called alicyclic heterocyclic compounds. Compound: 14481-08-4, is researched, Molecular C22H38NiO4, about Addition Polymerization of Norbornene-Type Monomers Using Neutral Nickel Complexes Containing Fluorinated Aryl Ligands, the main research direction is nickel complex fluorinated aryl ligand norbornene addition polymerization catalyst.Product Details of 14481-08-4.

The strong Lewis acid B(C6F5)3 was found to activate complexes of nickel toward the polymerization of norbornene-type monomers. The active species in this reaction is created by the transfer of C6F5 from boron to nickel. As a result, a class of neutral, single-component nickel complexes was developed containing two electron-withdrawing aryl ligands that polymerize norbornene and norbornenes with functional pendant groups. Active complexes include Ni(C6F5)2(PPh2CH2C(O)Ph), (η6-toluene)Ni(C6F5)2, and Ni(2,4,6-tris(trifluoromethyl)phenyl)2(1,2-dimethoxyethane). In the case of (η6-toluene)Ni(C6F5)2, isolation and characterization of low mol. weight norbornene polymers, using ethylene, indicated that each polymer chain contained a C6F5 headgroup. This points to the initiation step as being the insertion of norbornene into the Ni-C6F5 bond. The polymer microstructure as revealed by 1H and 13C NMR spectrometry is entirely different from that produced using the cationic nickel catalyst, [(η3-crotyl)Ni(1,4-COD)]PF6. This difference in microstructure led to improved mech. properties for 80:20 copolymers of norbornene and 5-triethoxysilylnorbornene.

There is still a lot of research devoted to this compound(SMILES：CC(C)(C1=O[Ni+2]2(O=C(C(C)(C)C)[CH-]1)O=C([CH-]C(C(C)(C)C)=O2)C(C)(C)C)C)Product Details of 14481-08-4, and with the development of science, more effects of this compound(14481-08-4) can be discovered.

Reference:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

The three-dimensional configuration of the ester heterocycle is basically the same as that of the carbocycle. Compound: (11bR)-N,N-Bis[(1R)-1-phenylethyl]dinaphtho[2,1-d:1′,2′-f][1,3,2]dioxaphosphepin-4-amine(SMILESS: C[C@@H](N(P1OC2=CC=C3C=CC=CC3=C2C4=C5C=CC=CC5=CC=C4O1)[C@@H](C6=CC=CC=C6)C)C7=CC=CC=C7,cas:415918-91-1) is researched.Related Products of 610-09-3. The article 《Hydrovinylation of Norbornene. Ligand-Dependent Selectivity and Asymmetric Variations》 in relation to this compound, is published in Organic Letters. Let’s take a look at the latest research on this compound (cas:415918-91-1).

Norbornene undergoes Ni-catalyzed (1-2 mol% allylnickel bromide/phosphine/NaBARF, sodium tetrakis[3,5-bis(trifluormethyl)phenyl]borate or AgSbF6, 1 bar ethylene, -50 °C) hydrovinylation (>97% yield), giving either a 1:1 or a 2:1 (norbornene/ethylene) adduct depending on the size of the phosphine. Use of binaphthol-derived phosphoramidite ligand results in up to 80% ee for the 1:1 adduct. The course of the reaction is highly dependent on the ligand (size and configuration of the appendages) and the counteranion present.

There is still a lot of research devoted to this compound(SMILES：C[C@@H](N(P1OC2=CC=C3C=CC=CC3=C2C4=C5C=CC=CC5=CC=C4O1)[C@@H](C6=CC=CC=C6)C)C7=CC=CC=C7)Product Details of 415918-91-1, and with the development of science, more effects of this compound(415918-91-1) can be discovered.

Reference:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

In organic chemistry, atoms other than carbon and hydrogen are generally referred to as heteroatoms. The most common heteroatoms are nitrogen, oxygen and sulfur. Now I present to you an article called Axial-to-Central Chirality Transfer for Construction of Quaternary Stereocenters via Dearomatization of BINOLs, published in 2019-11-15, which mentions a compound: 415918-91-1, mainly applied to spiro benzochromene naphthalenone asym synthesis; binaphthol dearomatization axial chirality transfer propargyl carbonate enantioselective spirocyclization, Computed Properties of C36H30NO2P.

Herein, an axial-to-central chirality transfer strategy for the synthesis of chiral quaternary stereocenters via dearomatization of (S)-BINOLs is disclosed. The reaction of (S)-BINOL with a wide range of propargyl carbonates I (R = Me, cyclopropyl, Ph, 4-ClC6H4, 1-naphthyl, 2-benzothienyl, etc.) proceeded smoothly to afford chiral spiro compounds II in high yields with excellent enantioselectivities. In addition, the strategy was extended to kinetic resolution of rac-BINOLs albeit with moderate s value.

There is still a lot of research devoted to this compound(SMILES：C[C@@H](N(P1OC2=CC=C3C=CC=CC3=C2C4=C5C=CC=CC5=CC=C4O1)[C@@H](C6=CC=CC=C6)C)C7=CC=CC=C7)Computed Properties of C36H30NO2P, and with the development of science, more effects of this compound(415918-91-1) can be discovered.

Reference:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

The reaction of an aromatic heterocycle with a proton is called a protonation. One of articles about this theory is 《High Grade Serous Ovarian Carcinoma in a Liver Transplant Recipient Patient: A Case Report and Review of Literature.》. Authors are Tokalioglu, Abdurrahman Alp; Ozgun, Yigit Mehmet; Celik, Fatih; Akdogan, Meral; Bostanci, Erdal Birol; Turan, Taner; Turkmen, Osman.The article about the compound:cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II)cas:41575-94-4,SMILESS:O=C1C2(CCC2)C(O[Pt]O1)=O.N.N).Category: esters-buliding-blocks. Through the article, more information about this compound (cas:41575-94-4) is conveyed.

According to GLOBOCAN 2020 data, the incidence of ovarian cancer is 1.6%. Ovarian cancer ranks 19th in incidence and 15th in mortality with a rate of 2.1%. High-grade serous ovarian cancer is the most common subtype of malignant ovarian tumors, and around 70% to 80% of all ovarian malignancies are included in this group. The incidence of gynecologic malignancies in liver transplant recipients is between 0% and 1.5%, and the duration of diagnosis for gynecologic cancer after transplantation is between 1 and 59 months. A 52-year-old patient was admitted to our hospital complaining of a periumbilical nodule. Her medical history revealed she had a cadaver liver transplantation in 2003 because of cirrhosis due to hepatitis B. On her physical examination, an erythematous nodular lesion was observed in the umbilical region. Ultrasonography demonstrated diffuse ascites and approximately 30 mm of a soft tissue density with lobulated contours located on the periumbilical skin. Both cytology and biopsy results were reported consistent with high-grade serous ovarian cancer. She underwent an operation, she had no problems during the postoperative follow-ups, and she was discharged on the eighth postoperative day. According to the 2018 International Federation of Gynecology and Obstetrics staging criteria for ovarian cancer, the patient’s cancer was stage IVB. The patient received 6 cycles of adjuvant chemotherapy that included carboplatin (AUC = 6) and paclitaxel (175 mg/m2). The patient was evaluated as having a complete response according to Response Evaluation Criteria in Solid Tumors. The patient has been disease-free for 11 months after diagnosis.

There is still a lot of research devoted to this compound(SMILES：O=C1C2(CCC2)C(O[Pt]O1)=O.N.N)Category: esters-buliding-blocks, and with the development of science, more effects of this compound(41575-94-4) can be discovered.

Reference:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

Benetis, N.; Kowalewski, J.; Nordenskioeld, L.; Edlund, U. published the article 《Nuclear spin relaxation in a paramagnetic nickel(II) complex. An experimental test of new theoretical models》. Keywords: nuclear spin relaxation methylheptanedionato nickel.They researched the compound: Bis(2,2,6,6-tetramethyl-3,5-heptanedionato)nickel(II)( cas:14481-08-4 ).Related Products of 14481-08-4. Aromatic heterocyclic compounds can be divided into two categories: single heterocyclic and fused heterocyclic. In addition, there is a lot of other information about this compound (cas:14481-08-4) here.

Paramagnetic relaxation enhancement data are reported for 15N and 1H in aniline in the presence of bis(2,2,6,6-tetramethylheptanedionato)nickel(II). For 15N, the spin-lattice T1 as well as spin-spin relaxation rates are reported at 2.35 and 5.875 T and of 244-356 K. For 1H T1 data at 2 fields (5.875 and 9.4 T) 263-333 K. The exptl. data are fitted to a new theor. model, not invoking the concept of electron spin relaxation times, which is valid in the slow motion regime for the electron spin. The parameters obtained form a consistent set and have reasonable values, but the 15N results could not be fitted by using the conventional model based on the modified Solomon-Bloembergen equations.

There is still a lot of research devoted to this compound(SMILES：CC(C)(C1=O[Ni+2]2(O=C(C(C)(C)C)[CH-]1)O=C([CH-]C(C(C)(C)C)=O2)C(C)(C)C)C)Related Products of 14481-08-4, and with the development of science, more effects of this compound(14481-08-4) can be discovered.

Reference:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

Zharkova, G. I.; Baidina, I. A.; Stabnikov, P. A. published an article about the compound: Bis(2,2,6,6-tetramethyl-3,5-heptanedionato)nickel(II)( cas:14481-08-4,SMILESS:CC(C)(C1=O[Ni+2]2(O=C(C(C)(C)C)[CH-]1)O=C([CH-]C(C(C)(C)C)=O2)C(C)(C)C)C ).Reference of Bis(2,2,6,6-tetramethyl-3,5-heptanedionato)nickel(II). Aromatic heterocyclic compounds can be classified according to the number of heteroatoms or the size of the ring. The authors also want to convey more information about this compound (cas:14481-08-4) through the article.

New volatile β-iminoketonate complexes of Ni(L)2 and Pd(L)2 were obtained, where HL is β-Aminovinylketone, CMe3C(NH2):CHC(O)CMe3, 2,2,6,6-tetramethyl-3-amino-4-hepten-5-one. Synthesis of the compound is described, and element anal., DTA, and IR spectral data are given. The complexes were studied by XRPA and XRD. The structures are mol., consist of the trans complexes, and are isostructural. The central atoms have a square plane environment with a (MO2N2) coordination unit. The M-O and M-N distances and the N-M-O valence chelate angles are equal, 1.834 Å, 1.848 Å, and 94.2° for Ni(L)2 and 1.972 Å, 1.975 Å, and 92.4° for Pd(L)2.

There is still a lot of research devoted to this compound(SMILES：CC(C)(C1=O[Ni+2]2(O=C(C(C)(C)C)[CH-]1)O=C([CH-]C(C(C)(C)C)=O2)C(C)(C)C)C)Reference of Bis(2,2,6,6-tetramethyl-3,5-heptanedionato)nickel(II), and with the development of science, more effects of this compound(14481-08-4) can be discovered.

Reference:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

The three-dimensional configuration of the ester heterocycle is basically the same as that of the carbocycle. Compound: cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II)(SMILESS: O=C1C2(CCC2)C(O[Pt]O1)=O.N.N,cas:41575-94-4) is researched.Synthetic Route of C36H30NO2P. The article 《First-in-human phase 1 study of budigalimab, an anti-PD-1 inhibitor, in patients with non-small cell lung cancer and head and neck squamous cell carcinoma》 in relation to this compound, is published in Cancer Immunology Immunotherapy. Let’s take a look at the latest research on this compound (cas:41575-94-4).

Budigalimab is a humanized, recombinant IgG1 monoclonal antibody targeting programmed cell death protein 1 (PD-1). We present the safety, efficacy, pharmacokinetic (PK), and pharmacodynamic data from patients enrolled in the head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer (NSCLC) expansion cohorts of the phase 1 first-in-human study of budigalimab monotherapy (NCT03000257; registered 15 Dec. 2016). Patients with recurrent/metastatic HNSCC or locally advanced/metastatic NSCLC naive to PD-1/PD-1-ligand inhibitors were enrolled; patients were not selected on the basis of oncogene driver mutations or PD-L1 status. Budigalimab was administered at 250 mg i.v. Q2W or 500 mg i.v. Q4W until disease progression/unacceptable toxicity. The primary endpoints were safety and PK; the secondary endpoint was efficacy. Exploratory endpoints included biomarker assessments. In total, 81 patients were enrolled (HNSCC: N = 41 [PD-L1 pos.: n = 19]; NSCLC: N = 40 [PD-L1 pos.: n = 16]); median treatment duration was 72 days (range, 1-617) and 71 days (range, 1-490) for the HNSCC and NSCLC cohorts, resp. The most frequent grade ≥ 3 treatment-emergent adverse event was anemia (HNSCC: n = 9, 22%; NSCLC: n = 5, 13%). Both dosing regimens had comparable drug exposure and increased interferon gamma-induced chemokines, monokine induced by gamma interferon, and interferon-gamma-inducible protein 10. Objective response rates were 13% (90% CI, 5.1-24.5) in the HNSCC cohort and 19% (90% CI, 9.2-32.6) in the NSCLC cohort. Median progression-free survival was 3.6 mo (95% CI, 1.7-4.7) and 1.9 mo (95% CI, 1.7-3.7) in the HNSCC and NSCLC cohorts. The safety, efficacy and biomarker profiles of budigalimab are similar to other PD-1 inhibitors. Development of budigalimab in combination with novel anticancer agents is ongoing.

There is still a lot of research devoted to this compound(SMILES：O=C1C2(CCC2)C(O[Pt]O1)=O.N.N)Formula: C6H12N2O4Pt, and with the development of science, more effects of this compound(41575-94-4) can be discovered.

Reference:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics